BCYC
Bicycle Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$4.30
+1.42%Year over year
Reported trailing growth
- Revenue
- +217.4%
- EBITDA
- +30.8%
- EBIT
- +27.0%
- EPS
- +22.0%
- Free cash flow
- +2.4%
- Operating cash flow
- +1.4%
Forward estimates
Based on analyst estimates
- Revenue
- -73.8%
- EBITDA
- +26.6%
- EPS
- +27.0%
Three-year CAGR
- Revenue
- +71.2%
- EBITDA
- -28.7%
- EBIT
- -18.0%
- Net income
- -29.5%
- EPS
- -8.6%
- Free cash flow
- -52.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026